Ultime notizie per Paragon 28 (NYSE:FNA) Azioni

Paragon 28

Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, Charcot, fracture fixation, hallux valgus, hammertoe, and flat foot. The company's suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. Geographically the company generates the majority of its revenue from the United States.

Paragon 28 Inc

EVOLUTIONARY GENOMICS INC by Evolutionary Genomics, Inc.

Evolutionary Genomics Inc

FOUR NINES GOLD INC by FOUR NINES GOLD INC.

Four Nines Gold Inc

FNAC DARTY ORD

Fnac Darty SA

HC Wainwright &amp; Co. analyst Edward White maintains Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) with a Buy and raises the price target from $21 to $22.

News

Price Target

Analyst Ratings

AURA

HC Wainwright & Co. Maintains Buy on Aura Biosciences, Raises Price Target to $22

The collaboration supports the licensing of part of Curiosity Stream&#39;s content portfolio in China, Hong Kong, and Macau, bringing 56 unique titles, amounting to 148 hours of premium factual content, to audiences across these territories through various platforms. The deal encompasses a diverse range of programming, from short-form documentary series to premium long-form content.

CURI

Curiosity Inks Strategic Distribution Partnership With Off The Fence; Deal Broadens Company's Footprint Across China, Hong Kong, And Macau

Guidance

CVS's Q3 Results Won't Meet Wall Street's Expectations; Plans To Back Away From Current 2024 Guidance

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates DRDGold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRD#NYSE">DRD</a>) with a Buy and maintains $13.25 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on DRDGold, Maintains $13.25 Price Target

Management

CVS Naming Caremark President David Joyner As Its New CEO

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) with a Buy and maintains $1.5 price target.

HC Wainwright & Co. Reiterates Buy on Avino Silver & Gold Mines, Maintains $1.5 Price Target

Biotech

Large Cap

Health Care

General

The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion, Recommending Approval Of Novo Nordisk's Alhemo (Concizumab) As The First Once-Daily Subcutaneous Prophylactic Treatment For People Aged 12 Years Or Older With Hemophilia A Or B With Inhibitors.

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates First Majestic Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) with a Buy and maintains $8.5 price target.

HC Wainwright & Co. Reiterates Buy on First Majestic Silver, Maintains $8.5 Price Target

The combined companies for the trailing twelve months have generated $235 million in revenue, increasing approximately&nbsp;25%&nbsp;quarter-over-quarter.

BTTR

Better Choice Expects Combined 2025 Pro Forma Basis Revenue And EBITDA To Be Approximately +$270M, And +$10M, Respectively

Better Choice Says Continues To Make Progress Towards Closing Of Its Acquisition Of SRx Health Solutions; Expects Transaction To Close In Late Q4 Of This Year Or Early Q1 Of 2025

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and maintains $23 price target.

NMRA

Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target

Based on sales trends and order intake in recent years, it expects further market share gains with domestic Chinese OEMs in the coming years.
With the seasonally strong fourth quarter remaining of the year, it reaffirms&nbsp;guidance of around 9.5-10.0% adjusted operating margin for 2024, but to be at the low end of this range.
&nbsp;

Autoliv Now Expects Full Year 2024 Organic Sales Growth To Be 1% Instead Of Previously Expected 2% Due To Unfavorable Market Mix Development

Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.53 by 7.55 percent. This is a 16.33 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $1.87 billion which beat the analyst consensus estimate of $1.80 billion by 3.78 percent. This is a 0.54 percent increase over sales of $1.86 billion the same period last year.

Earnings

Earnings Beats

Regions Finl Q3 Adj $0.57 Beats $0.53 Estimate, Sales $1.87B Beat $1.80B Estimate

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

ALNY

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) reported quarterly earnings of $1.84 per share which missed the analyst consensus estimate of $1.95 by 5.64 percent. The company reported quarterly sales of $2.56 billion which beat the analyst consensus estimate of $2.53 billion by 0.89 percent. This is a 1.58 percent decrease over sales of $2.60 billion the same period last year.

Earnings Misses

Autoliv Q3 2024 Adj EPS $1.84 Misses $1.95 Estimate, Sales $2.56B Beat $2.53B Estimate

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.

GEVO

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) with a Buy and maintains $22 price target.

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target

Needham analyst Mayank Tandon maintains WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) with a Buy and lowers the price target from $70 to $60.

Needham Maintains Buy on WNS (Hldgs), Lowers Price Target to $60

Needham analyst Kyle Peterson reiterates Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Buy and maintains $350 price target.

Needham Reiterates Buy on Equifax, Maintains $350 Price Target

Needham analyst Mike Matson downgrades Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) from Buy to Hold and maintains the price target from $86 to $86.

Downgrades

Needham Downgrades Boston Scientific to Hold, Maintains Price Target to $86

The latest update is out from Paragon 28 (FNA). Chadi Chahine has been named the new CFO and EVP of Supply Chain Operations at Paragon 28, bringing...

Paragon 28 Announces New CFO and Operational Efficiency Plan

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Paragon 28 (NYSE:<a href="https://investorplace.com/stock-quotes/fna-stock-quote/">FNA</a>) just reported results for the second quarter of 2024.<ul><li>Paragon 28 reported earnings per share of -17 cents. This met the analyst estimate for EPS of -17 cents.</li><li>The company reported revenue of $61.02 million.</li><li>This was 1.57% better than the analyst estimate for revenue of $60.07 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/fna-stock-earnings-paragon-28-for-q2-of-2024/">FNA Stock Earnings: Paragon 28 Meets EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

FNA Stock Earnings: Paragon 28 Meets EPS, Beats Revenue for Q2 2024

David Turkaly, an analyst from JMP Securities, reiterated the Buy rating on Paragon 28 (FNA – Research Report). The associated price target is $20....

Buy Rating Affirmed for Paragon 28 Amid Strong Financial Performance and Strategic Growth

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arrowhead Pharmaceuticals (ARWR – Research Report) a...

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Paragon 28 (FNA)

Paragon 28 reports Q2 results, names Chadi Chahine as CFO

Bank of America Securities analyst Craig Bijou reiterated a Buy rating on Paragon 28 (FNA – Research Report) today and set a price target of $12.00...

Buy Rating Affirmed for Paragon 28 Amid Revenue Growth and Positive EBITDA Outlook

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Paragon 28 (FNA – Research Report), ADMA Biologics (...

Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), ADMA Biologics (ADMA) and Veracyte (VCYT)

Paragon 28, Inc. (FNA) Q2 2024 Earnings Call Transcript

Paragon 28, Inc. 2024 Q2 - Results - Earnings Call Presentation

Warning: FNA is at high risk of performing badly

ADMA

ARWR

VCYT

Legal

Press Releases

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Paragon 28

Paragon 28 Launches the Phantom® Fibula Nail System for Less Invasive Fracture Repair

Paragon 28, Inc. Shareholders who Lost Money on Their Investments are Encouraged to Contact The Denver Law Office Johnson Fistel about the Class Action Lawsuit

FNA Stock News: Robbins LLP Reminds Investors with Large Large Losses of the Class Action Against Paragon 28, Inc.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Allarity, Metagenomi, Paragon 28, and New Fortress and Encourages Investors to Contact the Firm

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Paragon 28, Inc. (FNA)

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Paragon 28, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – FNA

Comments

Paragon 28

Notizie

Ultime notizie per Paragon 28 (NYSE:FNA) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO